Delcath Systems, Inc. — FY2011 Form 10-K Summary
Business context and reporting period
Development-stage oncology pharmaceutical and medical-device company focused on the Delcath chemosaturation system, initially for liver cancers. The system delivers high-dose regional chemotherapy with extracorporeal blood filtration. The filing covers the fiscal year ended December 31, 2011, with unaudited fourth-quarter data.
Delcath obtained the right to affix the CE Mark in April 2011 for the CHEMOSAT system, permitting marketing in the European Economic Area. The company remained pre-revenue and had not obtained FDA approval in the United States. Management was preparing to resubmit its 505(b)(2) NDA in the second quarter of 2012 after receiving a Refusal to File letter in February 2011.
Financial performance and liquidity
| Metric | FY2011 | FY2010 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $46.5 million | $30.7 million |
| Operating loss | $46.5 million | $30.7 million |
| Net loss | $30.9 million | $46.7 million |
| Basic and diluted loss per share | $0.68 | $1.20 |
| Cash used in operating activities | $37.4 million | $24.1 million |
| Cash, cash equivalents and certificates of deposit | $30.8 million | $47.1 million |
General and administrative expense was $21.3 million, up from $13.2 million, while research and development expense was $25.2 million, up from $17.6 million. No meaningful revenue or profit margins were reported because the company had no operating revenue.
At December 31, 2011, cash and cash equivalents were $25.8 million, including approximately $25.4 million in money-market funds, and certificates of deposit were $5.0 million. Current assets were $32.0 million, current liabilities were $8.8 million, and stockholders’ equity was $26.1 million. The filing does not report conventional interest-bearing debt; current liabilities included a $2.4 million warrant derivative liability, $5.5 million of accrued expenses and $0.9 million of accounts payable.
Financing activities provided $23.6 million in 2011, primarily from the sale of common stock. The company had approximately $39.75 million available under its existing shelf registration at year-end and subsequently sold approximately $2.0 million of stock through its at-the-market program through March 5, 2012.
Fourth-quarter and year-over-year changes
- Fourth-quarter 2011 operating loss was $16.0 million, compared with $9.5 million in the fourth quarter of 2010.
- Fourth-quarter 2011 net loss was $15.3 million, or $0.32 per share, compared with $15.3 million, or $0.36 per share, in fourth-quarter 2010.
- FY2011 net loss declined by $15.8 million, or 34%, primarily because the company recorded $15.6 million of derivative instrument income in 2011 versus $16.0 million of derivative expense in 2010. This was a non-cash mark-to-market item and did not reflect operating improvement.
- Operating costs increased $15.7 million year over year, driven by European commercialization preparations, additional FDA safety-data and remonitoring work, expanded research and development, and headcount growth from 47 to 80 employees.
- Cash used in operations increased 55.2% year over year, while total cash, cash equivalents and certificates of deposit declined $16.3 million.
Guidance, outlook, commentary and risks
- Management stated that available capital was expected to fund operating activities through 2012, but additional working capital would likely be required to continue operations and fully commercialize the product.
- The company expected to submit the revised NDA to the FDA in the second quarter of 2012 and intended to request Priority Review. Neither filing acceptance nor approval was assured.
- European commercialization was in its early stages. The company had training and marketing agreements with cancer centers in Italy and Germany; five European patients received treatments in February 2012.
- The Generation 2 CHEMOSAT CE Mark amendment remained under review by the notified body. The company also pursued approvals in Australia, New Zealand and several Asian and Latin American markets.
- Clinical evidence included a Phase III median hepatic progression-free survival of 8.0 months versus 1.6 months for best alternative care, based on investigator assessment. These results did not eliminate regulatory, safety, reimbursement or commercialization risks.
- Key risks include continued operating losses and cash burn, dependence on additional financing, FDA rejection or delay, future clinical-trial requirements, limited commercialization experience, uncertain reimbursement, dependence on suppliers and a sole EEA melphalan manufacturer, manufacturing and quality requirements, competition, product-liability exposure, patent expirations and potential equity dilution.
- The company had approximately $11.9 million of operating lease obligations and a $1.0 million 2012 payment obligation under its NCI research agreement. It also was required to maintain an $881,297 letter of credit under its New York office lease.
Most important facts to verify
- Whether the FDA accepted and substantively reviewed the resubmitted NDA, and the eventual regulatory outcome.
- Actual European sales, procedure volumes, reimbursement status and gross margins following the initial patient treatments.
- Cash burn, financing proceeds and remaining liquidity relative to commercialization and clinical-trial needs.
- The effect of warrant accounting and potential dilution from outstanding warrants, options and future equity offerings.
- Manufacturing capacity, supplier continuity, melphalan availability and regulatory status of the Generation 2 system.
- Whether additional clinical trials or safety data are required for U.S. approval or additional indications.